BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Dirty soda started as a Mormon alternative to booze. Now it's everywhere. - 2How did this 20-light-year-wide 'Diamond Ring' form in space? Maybe a cosmic bubble burst
- 3Manual for Notorious Fragrances: Immortal Aromas
- 4New science points to 4 distinct types of autism
- 5Improving as a Cook: Culinary Experiences in the Kitchen
- The 15 Most Rousing TED Chats on Self-awareness
- EU health regulator urges immediate vaccinations amid early surge in flu cases
- 10 Hints for an Effective New employee screening
- Golan resident convicted of spying for Iran after passing tank movement, missile-impact data
- Charli xcx teases new film ‘The Moment’: What to know about the A24 movie
- When a sperm whale gives birth, the mother gets help from her friends
- Vote In favor of Your Favored Pet Consideration Administration
- Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- What's your #1 tone
